logo

Athenex, Inc. (ATNX)



Trade ATNX now with
  Date
  Headline
3/1/2021 7:22:17 AM Athenex Q4 Loss Per Share $0.53 Vs Loss $0.28 Last Year
3/1/2021 7:21:15 AM Athenex Gets FDA Complete Response Letter For Oral Paclitaxel Plus Encequidar For Metastatic Breast Cancer
2/18/2021 7:59:41 AM Almirall U.S. Launches Klisyri, A New, Innovative Topical Treatment For Actinic Keratosis
12/15/2020 7:11:23 AM Almirall :FDA Oks Klisyri, New Topical Treatment For Actinic Keratosis
9/1/2020 7:18:42 AM Athenex Announces FDA Acceptance For Filing Of NDA For Oral Paclitaxel And Encequidar In Metastatic Breast Cancer
6/13/2020 10:12:26 AM Athenex Oncology Launches Facing MBC Together Campaign
5/29/2020 8:15:31 AM Athenex Presents Interim Data From Oral Paclitaxel Phase II Study In Cutaneous Angiosarcom
4/9/2020 7:15:12 AM Athenex Says On Track To Submit NDA In Accordance With FDA's Guidance
3/9/2020 7:04:34 AM Athenex Reports FDA Acceptance For Filing Of US NDA For Tirbanibulin Ointment
9/4/2019 7:07:10 AM Athenex Names Daniel Lang MD To Lead TCR-T Immunotherapy Operations And Support Corporate Development Strategy
6/28/2019 7:06:20 AM Athenex Strategically Expands Presence In Europe And Latin America
6/24/2019 7:05:17 AM Athenex: FDA Allows IND Application For PT01 For Patients With Advanced Malignancies
3/11/2019 7:12:34 AM Athenex Q4 Net Loss Attributable To Athenex $27.1 Mln Or $0.41/Shr Vs Loss Of $28.3 Mln Or $0.49/Shr Last Year